The amygdala is a part of the brain that processes and lays down emotional memories. Dysfunction in the amygdala is responsible for anxiety related disorders such post-traumatic stress disorder. I will study the neural circuits in the amygdala using innovative recordings and stimulation techniques. These studies will provide insight into the circuits that underpin anxiety related neurological disorders and provide targets for development of novel anxiolytic agents.
Investigating The Potential Of Human Stem Cells To Repair The Degenerating Auditory Nerve After Deafness
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
One in four Australians is predicted to experience some form of hearing loss by 2050. Hearing loss is irreversible and the chief clinical treatment available for severe to profound hearing loss is a cochlear implant. However, cochlear implant efficacy is limited by the degeneration of the auditory nerve following hearing loss. Using stem cells, this project will develop techniques to restore function to the auditory nerve through replacement of the specialised cells that comprise it.
Neurogenesis In The Amygdala And Hippocampus: A Role In Learnt Fear?
Funder
National Health and Medical Research Council
Funding Amount
$780,396.00
Summary
It has long been thought that neurons are only born once and then slowly die. Learning and memory formation is thought to occur by changes in the strength of connections between living neurons. However, the hippocampus is now known to produce new neurons throughout life. We have found that neurons are also born in the adult amygdala. In this project we will study how neurogenesis affects learning and memory formation that involve the hippocampus and amygdala.
Sensitive Serum Markers For Improved Diagnosis, Monitoring And Screening For Early Detection Of Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$410,880.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. Mesothelioma is predicted to cost communities hundreds of billions of dollars in compensation. This disease is unusually difficult to diagnose and tends to be already quite advanced by the time patients present to the doctor with symptoms. Unfortunately, treatment options for the majority of patients are limited and most die within a year of diagnosis. ....The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. Mesothelioma is predicted to cost communities hundreds of billions of dollars in compensation. This disease is unusually difficult to diagnose and tends to be already quite advanced by the time patients present to the doctor with symptoms. Unfortunately, treatment options for the majority of patients are limited and most die within a year of diagnosis. In different forms of cancer, levels of certain proteins in the blood can be measured and have been shown to indicate the presence of tumour and in some cases the extent of tumour. These proteins are collectively known as tumour markers. Tumour markers for ovarian, prostate, breast and other cancers are used by doctors to help with the diagnosis of specific cancers, to monitor the patients response to treatment and to give a valuable early warning of remission or relapse. There is no tumour marker currently used for patients with mesothelioma. We have shown in early studies published in the prestigious journal The Lancet that soluble mesothelin related protein (SMRP) is actually elevated in more than 75% of mesothelioma patients and in less than 2% of patients with other cancer and non-cancer lung diseases. In this current project we plan to extend our studies looking at blood levels of SMRP to see if they will help in the care of patients with mesothelioma. So far we have done most of the work in a particular group of patients, but it is vital that the work be extended to other groups with different types and durations of exposure to asbestos and to different areas of the country. As part of that we need to test how stable the molecule is in blood samples, because if it is not very stable it wont be a very pratical test. We also plan to look at some other markers that have been clinically useful in other forms of cancer and we will try to identify new, novel mesothelioma specific markers. This work has the potential to impact on patient care in many centres of the world.Read moreRead less